As biopharma anticipates the “Facility of the Future,” a definition of what closed processing is, and quantification of its value, can be helpful information.
Sarah Le Merdy
Advertisement
Sarah Le Merdy is Systems and Single-Use Global Strategy Deployment Manager at Life Science business of Merck KgaA, Darmstadt, Germany.
Articles by Sarah Le Merdy
The combination of modular facilities and closed processing offers significant advantages in the production of biopharmaceuticals and is becoming a compelling option for manufacturing.
Advertisement
Latest Updated Articles
Perceptions and Considerations for Adopting Closed ProcessingPublished: March 30th 2023 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Challenges, Innovations, and Future Outlook of Biologics Formulations
2
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
3
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
4
Global Study Confirms Survival Advantage of Mogamulizumab in Advanced Mycosis Fungoides and Sézary Syndrome
5
